Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins
Open Access
- 1 February 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 79 (3), 546-556
- https://doi.org/10.1158/0008-5472.can-18-1492
Abstract
ROS1 fusion oncoproteins exhibit differential activation of MAPK signaling according to subcellular localization, with ROS1 fusions localized to endosomes the strongest activators of MAPK signaling.Keywords
Other Versions
Funding Information
- HHS | NIH | National Cancer Institute (NCI) (5F30CA210444-03)
- HHS | NIH | National Cancer Institute (NCI) (U01CA217882)
- HHS | NIH | National Cancer Institute (NCI) (U54CA224081)
- HHS | NIH | National Cancer Institute (NCI) (R01CA204302)
- HHS | NIH | National Cancer Institute (NCI) (R01CA211052)
- HHS | NIH | National Cancer Institute (NCI) (R01CA169338)
- Pew Charitable Trusts (None)
This publication has 50 references indexed in Scilit:
- The transcriptional landscape and mutational profile of lung adenocarcinomaGenome Research, 2012
- Fiji: an open-source platform for biological-image analysisNature Methods, 2012
- ROS1 Rearrangements Define a Unique Molecular Class of Lung CancersJournal of Clinical Oncology, 2012
- Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung CancerClinical Cancer Research, 2012
- Palmitoylated Ras proteins traffic through recycling endosomes to the plasma membrane during exocytosisThe Journal of cell biology, 2010
- The multifaceted roles of the receptor tyrosine kinase ROS in development and cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2009
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR MutantsPLoS Medicine, 2005
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLoS Medicine, 2005
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004